Get started
Author

Beverly L. Falcón

Observed names: B Falcon, B. Falcon, BEVERLY FALCON, BEVERLY L. FALCON, Beverly Falcon, Beverly Falcón, Beverly L Falcon, Beverly L. Falcon, Beverly L. Falcón, Falcon, Beverly
Observed institutions: Amgen (United States), Exelixis (United States), Eli Lilly (United States), University of California, San Francisco, University of Florida, Dana-Farber Cancer Institute, UCSF Helen Diller Family Comprehensive Cancer Center
ORCID: 0000-0001-7553-4013
Observed ORCID: 0000-0001-7553-4013
OpenAlex ID: A5019317536
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
2025 · Louis J. Aronne, Deborah Bade Horn, et al. · New England Journal of Medicine · 604
VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
2011 · Weon-Kyoo You, Barbara Sennino, et al. · Cancer Research · 259
PDF
Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
2010 · Hiroya Hashizume, Beverly L. Falcón, et al. · Cancer Research · 251
PDF
Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels
2009 · Beverly L. Falcón, Hiroya Hashizume, et al. · American Journal Of Pathology · 224
PDF
Sequential Loss of Tumor Vessel Pericytes and Endothelial Cells after Inhibition of Platelet-Derived Growth Factor B by Selective Aptamer AX102
2007 · Barbara Sennino, Beverly L. Falcón, et al. · Cancer Research · 155
PDF
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
2016 · Rachel S Kerr, Sharon Love, et al. · The Lancet Oncology · 150
Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
2010 · Angela Coxon, James Bready, et al. · Molecular Cancer Therapeutics · 148
Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents
2016 · Beverly L. Falcon, Sudhakar Chintharlapalli, et al. · Pharmacology & Therapeutics · 142
PDF
Reduced VEGF Production, Angiogenesis, and Vascular Regrowth Contribute to the Antitumor Properties of Dual mTORC1/mTORC2 Inhibitors
2011 · Beverly L. Falcon, Sharon Barr, et al. · Cancer Research · 91
PDF
The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma
2017 · Caitlin D. Lowery, Alle B. VanWye, et al. · Clinical Cancer Research · 69
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors
2018 · Bruce W. Konicek, Andrew R. Capen, et al. · Oncotarget · 53
PDF
Increased Vascular Delivery and Efficacy of Chemotherapy after Inhibition of Platelet-Derived Growth Factor-B
2011 · Beverly L. Falcon, Kristian Pietras, et al. · American Journal Of Pathology · 53
PDF
Angiotensin II type 2 receptor gene transfer elicits cardioprotective effects in an angiotensin II infusion rat model of hypertension
2004 · Beverly L. Falcón, Jillian M. Stewart, et al. · Physiological Genomics · 50
Stromal-Based Signatures for the Classification of Gastric Cancer
2016 · Mark T. Uhlik, Jiangang Liu, et al. · Cancer Research · 38
VEGF-A/VEGFR Inhibition Restores Hematopoietic Homeostasis in the Bone Marrow and Attenuates Tumor Growth
2016 · Rebekah K. O'Donnell, Beverly Falcon, et al. · Cancer Research · 22
Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition
2013 · Beverly L Falcon, Belinda O’Clair, et al. · Journal of Hematology & Oncology · 20
PDF
Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy
2019 · Caitlin D. Lowery, Wayne Blosser, et al. · Oncotarget · 19
PDF
High-content multiplexed tissue imaging and quantification for cancer drug discovery
2012 · Beverly L. Falcon, Julie Stewart, et al. · Drug Discovery Today · 19
Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition
2019 · Anthony S. Fischl, Xiaoen Wang, et al. · Molecular Cancer Therapeutics · 18
Angiotensin II Type 2 Receptor–Mediated Gene Expression Profiling in Human Coronary Artery Endothelial Cells
2005 · Beverly L. Falcón, Shereeni J. Veerasingham, et al. · Hypertension · 17
PDF
Weight reduction over time in tirzepatide‐treated participants by early weight loss response: Post hoc analysis in SURMOUNT‐1
2025 · Jamy Ard, Clare J. Lee, et al. · Diabetes Obesity and Metabolism · 16
Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight
2025 · Atul Malhotra, Ronald R. Grunstein, et al. · Sleep Medicine · 14
An In Vitro Cord Formation Assay Identifies Unique Vascular Phenotypes Associated with Angiogenic Growth Factors
2014 · Beverly L. Falcon, Michelle Swearingen, et al. · PLoS ONE · 9
PDF
A treat‐to‐target approach for obesity management: A post hoc analysis of the SURMOUNT ‐5 trial
2026 · Carel W. le Roux, Luca Busetto, et al. · Diabetes Obesity and Metabolism · 5
An Endothelial Cell/Mesenchymal Stem Cell Coculture Cord Formation Assay to Model Vascular Biology In Vitro
2017 · Michelle Swearingen, Beverly Falcon, et al. · Methods in molecular biology · 5
Works count: 144
Citation count: 2,479
H-index: 18
I10-index: 22
Year
Topic
Type